Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

Following dramatic success in many types of advanced solid tumors, interest in
immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given …

The binding of T cell immune checkpoint proteins programmed death 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by …

A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

Defects in pathways governing genomic fidelity have been linked to improved response to
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Objective Methionine metabolism is involved in a myriad of cellular functions, including
methylation reactions and redox maintenance. Nevertheless, it remains unclear whether …

POLE and POLD1 encode the catalytic and proofreading subunits of DNA polymerase ε and
polymerase δ, and play important roles in DNA replication and proofreading. POLE/POLD1 …